Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)
Completed · Phase 1, Phase 2 · NCT03790332
Conditions: Chronic Graft Versus Host Disease
At a glance
- Research payments reported, 2025
- $41,884
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 59
About the trial
- Sponsor
- Pharmacyclics LLC. (with Janssen Research & Development, LLC)
- Tested
- Ibrutinib (drug)
- Dates
- Started 2018-11-19; completion 2025-10-09
- Results posted
- Not yet
Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)
From ClinicalTrials.gov, last updated 2025-10-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $41,884 in research payments for this study in 2025 (14 payments).
Products named: Imbruvica
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Deepakbabu Chellapandian, M.D Pediatric Hematology & Oncology · Tampa, FL
- Sonali S. Chaudhury, MD Pediatric Hematology & Oncology · Chicago, IL
- David A. Jacobsohn, MD Pediatric Hematology & Oncology · Chicago, IL
- Shalini Shenoy, MD Pediatric Hematology & Oncology · Saint Louis, MO
- Eneida R. Nemecek, MD Pediatric Hematology & Oncology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $25,291
- All Childrens Research Institute Inc $5,461
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $4,962
- Ohsu Hospital and Clinics, OR $3,370
- Children's Research Institute Cri $2,800
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.